Cadila receives USFDA approval for diabetes tablets

Global Pharmaceutical company Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin HydrochlorideTablets. The tablets will be manufactured in Ahmedabad, India. 

Cadila will be manufacturing Linagliptin and Metformin HydrochlorideTablets (2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg, at the group's formulations manufacturing facility in SEZ, Ahmedabad. The tablet is advised to be used along with diet and exercise to improve blood sugar levels in adults with Type 2 diabetes mellitus. Cadila Healthcare is an Indian pharmaceutical company. The company is the fourth largest pharmaceutical company in India.
 

On Friday, the shares of Cadila Healthcare opened a little higher at Rs. 377.50 per share on the BSE versus Thursday’s close of Rs. 375.45. At 12:23 hours, the shares of Cadila traded at Rs. 378.10 up by 0.71 per cent or 2.65 points per share on the BSE. Its intraday high was Rs. 381.90 and intraday low was Rs. 375.50 per share. Its 52-week high was Rs. 515 and its 52-week low was at Rs. 332. The BSE Sensex was quoting 34,695.69, up by 682.90 points or 2.04 per cent.